Browse > Article
http://dx.doi.org/10.4014/jmb.1806.06046

Anti-Angiogenesis Effects Induced by Octaminomycins A and B against HUVECs  

Jang, Jun-Pil (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology)
Han, Jang Mi (Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University)
Jung, Hye Jin (Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University)
Osada, Hiroyuki (Chemical Biology Research Group, RIKEN Center for Sustainable Research Science)
Jang, Jae-Hyuk (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology)
Ahn, Jong Seog (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology)
Publication Information
Journal of Microbiology and Biotechnology / v.28, no.8, 2018 , pp. 1332-1338 More about this Journal
Abstract
In the course of studies to discover natural products with anti-angiogenic properties, two cyclic octapeptides, octaminomycins A (1) and B (2), were isolated from the cultures of Streptomyces sp. RK85-270. Octaminomycins suppressed the vascular endothelial growth factor (VEGF)-induced proliferation, adhesion, tube formation, migration, and invasion of HUVECs. Anti-angiogenic activity was futher confirmed in vivo by the chicken chorioallantoic membrane assay. We also identified that 1 and 2 inhibited the phosphorylation of VEGF receptor 2, AKT, and ERK1/2 and the expression and activities of MMP-2 and MMP-9. These results suggest that 1 and 2 may serve as potential scaffolds for the development of therapeutic agents to angiogenesis-dependent diseases.
Keywords
Octaminomycin; anti-angiogenesis; HUVEC; VEGF; secondary metabolites;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Staton CA, Reed MW, Brown NJ. 2009. Acritical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90: 195-221.   DOI
2 Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. 2004. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56: 549-580.   DOI
3 Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell. Biol. 7: 359-371.   DOI
4 Hass TL. 2005. Endothelial cell regulation of matrix metalloproteinases. Can. J. Physiol. Pharmacol. 83: 1-7.   DOI
5 Ne wman DJ, Cragg GM. 2016. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79: 629-661.   DOI
6 Cragg GM, Newman DJ. 2013. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 1830: 3670-3695.   DOI
7 Clardy J, Fischbach MA, Walsh CT. 2006. New antibiotics from bacterial natural products. Nat. Biotechnol. 24: 1541-1550.   DOI
8 Genilloud O, Gonzalez I, Salazar O, Martin J, Tormo JR, Vicente F. 2011. Current approaches to exploit actinomycetes as a source of novel natural products. J. Ind. Microbiol. Biotechnol. 38: 375-359.   DOI
9 Nett M, Ikeda H, Moore BS. 2009. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat. Prod. Rep. 26: 1362-1384.   DOI
10 Kerbel R, Folkman J. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739.   DOI
11 Jubb AM, Oates AJ, Holden S, Koeppen H. 2006. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 6: 626-635.   DOI
12 Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69: 4-10.   DOI
13 Jang JP, Nogawa T, Futamura Y, Shimizu T, Hashizume D, Takahashi S, et al. 2017. Octaminomycins A and B, cyclic octadepsipeptides active against Plasmodium falciparum. J. Nat. Prod. 27: 134.
14 Ferrara N. 2004. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9: 2-10.   DOI
15 Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18: 4-25.   DOI
16 Berqurs G, Hanahan D. 2008. Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer 8: 592-603.   DOI